Skip to main content
Interview with the Innovators

ESR1-Targeted Therapy

Sanjay Juneja, MD, on the Approval of ORSERDU™
Dr Sanjay Juneja, medical oncologist and hematologist, and Chief of Oncology at Baton Rouge General Hospital–Mary Bird Perkins Cancer Center in Baton Rouge, LA, also known as “The Onc Doc,” is a well-known healthcare influencer. In the video above, Dr Juneja provides his perspectives on key efficacy and safety data from the EMERALD trial, the importance of testing for ESR1 mutations, and what the approval of ORSERDU (elacestrant) means for patients. Read More ›

Sagar D. Sardesai, MBBS, on the Approval of ORSERDU™
Dr. Sardesai, medical oncologist at The Ohio State University in Columbus, OH, discusses key considerations relating to the approval of ORSERDU (elacestrant), including appropriate patient selection, the clinical relevance of ESR1 mutations, and key takeaways from the EMERALD trial. Read More ›

Chaitali Nangia, MD, on the Approval of ORSERDU™
Dr. Nangia, medical oncologist at Hoag Medical Group in Irvine, CA, discusses key efficacy and safety data from the EMERALD trial, the importance of liquid biopsy testing, and changes in practice brought upon by the approval of ORSERDU (elacestrant). Read More ›

Yuan Yuan, MD, PhD, on the Approval of ORSERDU™
Dr Yuan, medical oncologist in Southern California, discusses key data from the EMERALD trial, the clinical relevance of ESR1 mutations, and changes in practice brought on by the approval of ORSERDU (elacestrant). Read More ›